跳至主要内容
临床试验/NCT01939392
NCT01939392撤回2 期

Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the OneShot Renal Denervation System II

Medtronic Endovascular1 个研究点 分布在 1 个国家开始时间: 2013年9月1日最近更新:
适应症

试验速览

阶段
2 期
状态
撤回
发起方
试验地点
1
主要终点
Major adverse event (MAE) rate through 30 days post randomization

研究概览

简要总结

This is a global, multi-center, prospective, randomized, controlled study of the safety and effectiveness of renal denervation with the OneShot Renal Denervation System in patients with uncontrolled hypertension.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Individual has a systolic blood pressure ≥ 160 mmHg based on an average of three office blood pressure readings.
  • Stable drug regimen including three or more anti-hypertensive medications including a diuretic

排除标准

  • Renal anatomy unsuitable for treatment
  • Presence of hemodynamically significant valvular heart disease for which reduction of blood pressure would be considered hazardous
  • Patient has Type I diabetes
  • Has scheduled or planned surgery within the next 6 months
  • Individual is pregnant nursing or plans to be pregnant

结局指标

主要结局

Major adverse event (MAE) rate through 30 days post randomization

时间窗: 30 days

Change in office systolic blood pressure (SBP) from baseline to 6 months post-randomization

时间窗: 6 months

次要结局

  • Reduction in SBP by >10 mmHg at 6 months(6 months)
  • Changes in office SBP and diastolic blood pressure (DBP) from baseline to follow-up visits(6, 12, 24, and 36 months)
  • Acute Procedural Safety(30 days)
  • Chronic procedural safety(6 months)

研究者

发起方
Medtronic Endovascular
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验